Credit: PROFESSOR JOHN ZAJICEK/Science Source
Welcome to The Multiple Sclerosis Journey. Join us for a multimedia exploration of where MS treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of MS care.
The Multiple Sclerosis Journey will examine new insights on the importance of early diagnosis as well as accurate identification of the four MS phenotypes and how their recognition impacts treatment selection. Join us as we examine the importance of maintaining brain health in sustaining wellness and ability among patients with MS. Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences.
And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.
The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.
Walk with us.
It’s taken almost 20 years, but the search for a widely usable, blood-based biomarker of multiple sclerosis (MS) disease activity is finally yielding results.
The way Frederick W. Foley, PhD, sees it, screening for cognitive problems in patients with multiple sclerosis has been taking a back seat to other routine clinical assessments largely because the deficits aren’t obvious in a typical clinical examination.
At first, Seattle-area resident Kellen Prouse blamed himself when sex became an ordeal after he was diagnosed with primary progressive multiple sclerosis. “I’m 27, and I’m saying, ‘What is wrong?’ It was hard to admit it was part of MS at first.”